HighGravityDataBioMarin Pharmaceutical — Aug 4, 2025 release
Fiscal 2025 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001048477-25-000088
Showing in the filing
Operating expenses
“expected to increase in the second half of 2025 vs. the first half of 2025”
Period
FY2025
Measure
Company-defined measure
Source
Prose
All guidance in this release · 9
VOXZOGO country access target for FY2027
“more than 60 countries”
VOXZOGO revenue for FY2025
“expected to drive higher VOXZOGO revenue in the second half of 2025 compared to the first half of 2025, and weighted to Q4”
Total Enzyme Therapies revenues for FY2025
“expected to remain robust”
Operating expenses for FY2025
“expected to increase in the second half of 2025 vs. the first half of 2025”
Total Revenues for FY2025
“$3,125 to $3,200”
Non-GAAP Operating Margin % for FY2025
“33% to 34%”
Non-GAAP Diluted EPS for FY2025
“$4.40 to $4.55”
VOXZOGO contribution to full-year 2025 Total… for FY2025
“$900 million to $935 million”
Non-GAAP Diluted EPS assumed Weighted-Averag… for FY2025
“approximately 200 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
GAAP SG&A decreased Y/Y due to higher 2024 restructuring expenses associated with the company’s revamped operating model, and Non-GAAP SG&A increased Y/Y to support the company’s ERP implementation and investment in business unit expansion initiatives. Operating expenses are expected to increase in the second half of 2025 vs. the first half of 2025 as clinical and commercial initiatives advance. • As a result of the completed acquisition of Inozyme on July 1, 2025, BioMarin expects to account for the transaction as an asset purchase and record the impact of acquired in-process research and development (IPR&D) charges in its third quarter 2025 financial results, which are subject to BioMarin’s financial statement closing procedures. The company expects to provide an update on full-year 2025 guidance items, including impact of the acquired IPR&D charges, in its third quarter 2025 earnings update. 3 • The company generated operating cash flows totaling $185 million in second quarter 2025, an increase of 55% compared to the same period in 2024. Total cash and investments at the end of the second quarter were approximately $1.9 billion, and increasing operating cash flow is expected to continue, supporting BioMarin’s priority of investment in innovation and future growth. • Today, BioMarin raised full-year 2025 guidance for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS. The improved guidance reflects continued growth in patient demand across the portfolio and the company’s commitment to generate increasing p
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.